Asset
FOSGEMCITABINE PALABENAMIDE
NuCana plc American Depositary Share
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04163900 | phase3 | terminated | 2019-12-24 | 2022-03-02 | NuCana plc | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer |
| NCT03146663 | phase2 | terminated | 2017-09-28 | 2019-12-31 | NuCana plc | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer |
FDA applications (0)
This company has no applications containing this asset.